WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2026 earnings release at approximately 5 p.m. ET on Tuesday, November 3, 2026. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 4. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.
Among those participating in the webcast presentation will be:
Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief financial officerDago Caceres, senior vice president, general manager, specialty additivesAlessandra Faccin, senior vice president, general manager, life sciences and intermediatesJim Minicucci, senior vice president, general manager, personal careSandy Klugman, director, investor relations To access the call by phone, please go to this registration link and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
The webcast and supporting materials will be accessible through the Investor Relations section of Ashland's website at http://investor.ashland.com. Following the live event, an archived version of the webcast and supporting materials will be available on the Ashland website for 12 months.
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
™ Trademark, Ashland, or its subsidiaries, registered in various countries.
Akcie Ashland za šest měsíců vzrostly o 30,2 % díky snižování nákladů, optimalizaci portfolia a silnějšímu mixu byznysu. Firma zároveň vykázala volný peněžní tok 103 milionů USD a zvýšila program zpětného odkupu na 1 miliardu USD.
Key Takeaways Ashland's shares soared 30.2% over six months, outpacing the industry.Cost reductions, portfolio optimization and a stronger business mix are boosting margin resilience.Ashland generated $103 million in free cash flow and doubled its buyback authorization to $1 billion. Ashland Inc.’s (ASH - Free Report) shares have rallied 30.2% over the past six months, outperforming the Zacks Chemical - Specialty industry’s 1.7% fall over the same period.
The price rally reflects improving margin resilience from cost reductions, portfolio optimization and a stronger business mix. Strong free cash flow generation and the new $1-billion share repurchase authorization are also supporting shareholder returns and investor confidence.
Image Source: Zacks Investment Research
Here are the key factors driving ASH stock.
Ashland’s Business Model Supports Profitable GrowthAshland’s shift from a functionally led organization to a business-unit-focused operating model continues to support its strategy of building a higher-margin specialty chemicals portfolio focused on attractive end markets. The model strengthens accountability at the business-unit level, enabling faster decision-making, closer customer alignment and improved execution.
Along with disciplined pricing, portfolio optimization and innovation in higher-value specialty ingredients, the approach is expected to support profitable growth and long-term value creation despite a challenging demand environment.
Ashland’s Cost Actions Boost Margin ResilienceAshland’s cost-reduction initiatives and portfolio optimization efforts continue to strengthen margins across its core businesses. Completed portfolio actions are improving product mix and structural margin resilience, while restructuring and manufacturing network optimization are helping drive greater efficiency.
Although a slower productivity ramp at the Hopewell facility has adversely impacted savings, management expects corrective actions to improve performance over time. The company remains focused on higher-value, consumer-oriented specialty ingredients and innovation-led products to support a stronger margin profile through disciplined cost management and an improved business mix.
Ashland Boosts Cash Flow While Expanding BuybacksAshland continues to prioritize free cash flow generation and stronger cash conversion. In the third quarter of fiscal 2026, operating activities generated $121 million in cash, while free cash flow reached $103 million. The company’s board also approved a new $1-billion share buyback authorization, doubling the previous $500-million program. Ashland had repurchased approximately $480 million of shares under the new authorization by the end of the fiscal third quarter.
Some better-ranked stocks in the Basic Materials space are Intrepid Potash, Inc. (IPI - Free Report) , Innospec Inc. (IOSP - Free Report) and Avient Corporation (AVNT - Free Report) . IPI sports a Zacks Rank #1 (Strong Buy), while IOSP and AVNT carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for IPI’s current-year earnings stands at $1.86 per share, implying a 29.2% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 37.4%. Shares of the company have fallen about 26.6% over the past six months.
The Zacks Consensus Estimate for IOSP’s current-year earnings has moved up 3.9% over the past 60 days. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 12.9%. Shares of IOSP have gained around 33.8% over the past six months.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pegged at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 3.4%. Shares of AVNT have surged around 15.9% over the past six months.
Ashland globálně uvedla na trh agrimer™ eco-disperse OD TVO™ polymeric dispersant, patentovaný disperzant z rostlinného oleje pro nevodné přípravky na ochranu rostlin. Produkt má zlepšit stabilitu, disperzi i udržitelnost formulací.
WILMINGTON, Del., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Continuing to scale its Transformed Vegetable Oils (TVO™) technology platform, Ashland Inc. (NYSE: ASH), today announced the global launch of agrimer™ eco-disperse OD TVO™ polymeric dispersant, a patented, nature-based dispersant developed for non-aqueous crop protection formulations. The introduction represents the latest commercial innovation from the TVO™ platform.
Agrimer™ eco-disperse OD was engineered so agrochemical formulators could address the growing industry challenge of delivering high-performance formulations while advancing sustainability goals and meeting increasingly complex regulatory expectations. The new polymeric dispersant enables effective stabilization and uniform dispersion of water-insoluble active ingredients, helping improve formulation performance, stability and application efficiency. The technology offers nature-based, inherently biodegradable and microplastic-free attributes that support the transition toward more environmentally responsible crop protection products.
Derived from transformed vegetable oil, agrimer™ eco-disperse OD helps improve dispersion stability, enhance leaf adhesion, coverage and rain fastness. The technology reduces common formulation challenges such as active ingredient settling and nozzle clogging, helping customers improve product consistency and field performance. Its broad formulation compatibility, ease of use and competitive cost-in-use profile provide additional flexibility for formulators developing suspension concentrates and other non-aqueous formulations.
"Ashland is again converting sustainable science into differentiated commercial solutions that create value for our customers," said Alessandra Faccin, senior vice president and general manager, Life Sciences, Ashland. "Agrimer™ eco-disperse OD expands our TVO™ platform with a patented technology that helps formulators achieve both sustainability and performance objectives. It reflects the type of innovation that strengthens our portfolio, supports profitable growth and advances our commitment to solving complex formulation challenges."
Jean J. Gulka, global business director, Life Sciences, Ashland, added, "The launch of agrimer™ eco-disperse OD represents more than a new product introduction. It reinforces the scalability and versatility of our innovative TVO™ technology platform and validates our strategy of investing in differentiated technologies that can address global sustainability trends while delivering tangible customer value. We continue to advance additional opportunities within the platform and view TVO™ as an important engine for future innovation and growth."
The commercialization of agrimer™ eco-disperse OD supports the Ashland strategy to Innovate and strengthen long-term value creation through innovation-led growth. Samples and commercial quantities are available globally. For more information or to request a sample, interested parties should contact their local Ashland representative or visit ashland.com/agrimer-eco-disperse-od
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its Annual Report to Stockholders, quarterly reports and other filings with the Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance and financial condition, its strategy as well as the economy and other future events or circumstances.
The risks and uncertainties we face which may cause our actual results to differ materially from the results expressed, projected, or implied in these forward-looking statements include, but are not limited to: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, geopolitical instability and armed conflict, and challenges associated with hiring and managing a diverse workforce across countries with differing laws, regulations, and cultural practices; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, and the inadvertent or accidental disclosure or loss of proprietary or sensitive information; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; and changes in taxation or adverse tax rulings. These risks and uncertainties also include, but are not limited to, the risk factors set forth in Item 1A. “Risk Factors” of Ashland’s most recent Form 10-K, and in our other periodic reports filed with the SEC. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update publicly any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this presentation.
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
™ Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:
Investor Relations:Media Relations:Sandy KlugmanCarolmarie C. Brown+1 (302) 594-7777+1 (302) [email protected]@ashland.com Ashland agrimer™ eco-disperse OD polymeric dispersant Press_Release_Global_Agrimer_EcoDisperseOD_Launch_FNL_20260922
Ashland agrimer™ eco-disperse OD polymeric dispersant Continuing to scale its Transformed Vegetable Oils (TVO™) technology platform, Ashland Inc. (NYSE: A...
Ashland ve 3. čtvrtletí vytvořila volný peněžní tok 103 mil. USD a schválila nový program zpětného odkupu akcií za 1 mld. USD. Firma ale čelí slabé průmyslové poptávce, logistickým tlakům a celním nákladům.
Key Takeaways ASH is sharpening its specialty chemicals portfolio through cost cuts and operational efficiency. Ashland generated $103 million in Q3 free cash flow and approved a new $1-billion share repurchase program. Weak industrial demand, logistics pressures and tariffs could weigh on margins and near-term performance. Ashland Inc. (ASH - Free Report) is focusing on cost savings, portfolio optimization and operational efficiency to strengthen margins and free cash flow while returning capital to stockholders through share repurchases. However, weak industrial demand, logistics pressures, tariff-related costs and concentration in higher-margin consumer-oriented businesses could weigh on future performance.
The company’s shares have gained 37.5% over a year against the industry’s 3.6% fall.
Image Source: Zacks Investment Research
Let’s find out why ASH stock is worth retaining at the moment.
Cost Savings and Portfolio Actions Bolster Margins for ASHAshland's shift to a business-unit-focused operating model supports its strategy of building a higher-margin specialty chemicals portfolio. The structure enables greater accountability, faster decision-making and stronger customer alignment. Combined with disciplined pricing, portfolio optimization and innovation, the model should support profitable growth and long-term value despite challenging demand.
Ashland's cost-reduction initiatives and portfolio-optimization actions continue to support margin resilience across its core businesses. Previously completed portfolio optimization measures are contributing to improved product mix and structural margin resilience, while ongoing restructuring and manufacturing network optimization initiatives are helping enhance operating efficiency.
Although the pace of savings has been affected by the slower productivity ramp at the Hopewell facility, management expects corrective actions to improve performance over time. The company continues to focus on higher-value, consumer-oriented specialty ingredients and innovation-driven product lines, positioning it to sustain an improved margin profile through operational discipline and a favorable business mix.
Ashland Strengthens Free Cash Flow and Shareholder ReturnsAshland is focused on increasing its free cash flow and enhancing free cash flow conversion. In the third quarter of fiscal 2026, operating activities generated $121 million in cash, while ongoing free cash flow totaled $103 million. Reaffirming its commitment to shareholder value, Ashland's board approved a new $1-billion share repurchase program, doubling its previous $500 million authorization. The company bought back about $480 million by the end of the fiscal third quarter under the new program.
Ashland Faces Concentration Risks and Tariff HeadwindsAshland's recent earnings resilience has been driven largely by its higher-margin Life Sciences and Personal Care segments, while industrial businesses continue to face weak demand. This concentration increases the risk that weaker consumer spending, customer destocking or regulatory challenges could disproportionately affect revenue and profitability. Diversification benefits remain limited as industrial end markets recover slowly.
Ashland also faces headwinds from U.S.-China trade and tariff policies, which are raising raw material costs and pressuring margins in Life Sciences and Personal Care. The company expects tariffs on U.S. sales to China to create a roughly $70 million headwind. While pricing actions and supply-chain adjustments may help offset the impact, prolonged tariff uncertainty and higher input costs could weigh on margins and near-term financial performance.
Ashland Faces Logistics Pressure and Weak Industrial DemandGlobal logistics challenges continue to pressure the specialty-chemicals sector, with higher freight costs, capacity constraints and delays raising operating expenses and weighing on margins.
Ashland also faces weak demand in its Specialty Additives business across construction, coatings and energy end markets. Despite pricing and cost-control measures, prolonged weakness could hurt volumes and earnings growth, offsetting strength in consumer-focused businesses.
Ashland Inc. Price and ConsensusASH’s Zacks Rank & Key PicksASH currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Worthington Steel, Inc. (WS - Free Report) , Innospec Inc. (IOSP - Free Report) and Avient Corporation (AVNT - Free Report) . WS currently sports a Zacks Rank #1 (Strong Buy), while IOSP and AVNT carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for WS’ current-year earnings stands at $3.4 per share, implying a 52.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, with the negative average surprise being 13.8%.
The Zacks Consensus Estimate for IOSP’s fiscal current-year earnings is pegged at $5.03 per share, implying a 4.55% year-over-year decrease. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 12.9%.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pegged at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 3.4%.
Ashland za 3. čtvrtletí fiskálního roku 2026 nesplnil odhad EPS, ale tržby vzrostly o 7 % na 497 milionů USD a překonaly konsensus. Firma zároveň potvrdila celoroční výhled tržeb i upravené EBITDA.
It has been about a month since the last earnings report for Ashland (ASH - Free Report) . Shares have added about 2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Ashland due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.
Ashland's Q3 Earnings Miss Estimates, Sales Beat on Volume GrowthAshland recorded income from continuing operations of $41 million or 89 cents per share for the third quarter of fiscal 2026 (ended June 30, 2026) against a loss from continuing operations of $719 million or $15.70 per share in the prior-year quarter.
Barring one-time items, adjusted earnings were $1.02 per share, down around 2% from the year-ago quarter figure of $1.04. The bottom line missed the Zacks Consensus Estimate of $1.03.
Sales increased 7% year over year to $497 million. The top line surpassed the Zacks Consensus Estimate of $486.2 million. Sales volumes rose 6%, with gains across all business units, while pricing increased around 1%. Favorable foreign currency movements contributed $3 million to sales.
Segment HighlightsLife Sciences: Sales in the segment increased 11% year over year to $180 million in the reported quarter. The figure surpassed the Zacks Consensus Estimate of $169.5 million. The year-over-year improvement was driven by higher volumes, broad-based pharmaceutical demand across regions and product categories, strength in high-purity excipients and injectables, customer order timing and favorable pricing.
Personal Care: Sales in the division increased 5% year over year to $155 million. The metric beat the consensus estimate of $154 million. Growth reflected higher volumes across end markets and regions, including strength in skin care, hair care, oral care and home care, along with robust demand for biofunctional actives and microbial protection.
Specialty Additives: Sales in the segment increased 4% year over year to $136 million and missed the Zacks Consensus Estimate of $139 million. Favorable pricing and mix, continued growth in coatings and performance specialties, share gains and strong commercial execution more than offset weakness in construction and energy and resources.
Intermediates: Sales in the segment rose 12% year over year to $37 million and beat the consensus estimate of $34 million. The increase reflected higher merchant sales, supported by improving N-Methyl-2-pyrrolidone demand from North American electric-vehicle battery and energy-storage customers, as well as higher captive butanediol sales.
FinancialsCash flows provided by operating activities were $121 million, up from $114 million in the prior-year quarter, primarily reflecting working-capital improvements. Ongoing free cash flow was $103 million compared with $108 million a year ago, with conversion remaining above 90% in both periods. Ashland ended the quarter with net leverage of 2.4 times, returning to its long-term target range.
OutlookFor fiscal 2026, Ashland reaffirmed sales guidance of $1.835-$1.870 billion and adjusted EBITDA outlook of $385-$400 million. The company revised its adjusted EPS outlook, excluding intangible amortization, to low-to-mid-single-digit growth from mid-to-high-single-digit growth due to a higher tax rate associated with unfavorable discrete items. Ongoing free cash flow conversion is expected to exceed 50% of adjusted EBITDA, with capital expenditures of approximately $90 million. Management expects continued sequential improvement in the fourth quarter as operations improve and recent pricing actions gain traction.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a flat trend in estimates review.
VGM ScoresCurrently, Ashland has a subpar Growth Score of D, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook Ashland has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Ashland uvedla permexa™ sodium caprate, pomocnou látku pro podporu vývoje a komercializace perorálních peptidů, biologik a léčiv s nízkou propustností, včetně agonistů GLP-1.
WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.
The launch comes at a time of significant market momentum in oral peptide and biologics development. Pharmaceutical companies continue to invest heavily in oral alternatives to injectable therapies, driven by the potential to improve patient convenience, enhance treatment adherence and unlock new therapeutic opportunities. As a result, pipelines across GLP-1’s, diabetes and weight loss, metabolic disorders, endocrine therapeutics and other peptide-based medicines continue to expand.
Developers continue to face important challenges as programs move from concept through development and manufacturing, despite growing investment and encouraging clinical progress. Permeability enhancement remains critical for oral drug products, but formulation consistency, process robustness and scalability are increasingly recognized as key barriers to successful commercialization.
Ashland permexa™ sodium caprate was engineered to help address these challenges by combining established sodium caprate functionality with improved pharmaceutical processing performance. The excipient is designed with an IP-protected process to support more robust tablet manufacturing through improved powder flow, enhanced compressibility and greater formulation consistency, while maintaining the permeability enhancement characteristics required for oral drug delivery applications. The result is a solution intended not only for laboratory success, but also for real-world pharmaceutical development and manufacturing environments where reproducibility, scalability and process robustness are essential.
The Ashland launch follows strong interest from pharmaceutical developers worldwide. Ahead of the commercial launch, the company recorded engagement with multiple pharmaceutical, biotech and CDMO organizations globally, spanning sampling activities, technical evaluations, pre-launch sales, benchmarking studies and formulation development discussions. Customer feedback has been overwhelmingly positive on the product’s differentiated properties.
“The rapid growth of oral peptide development is creating demand for excipients that support both biological performance and pharmaceutical manufacturability,” said Alessandra Faccin, senior vice president and general manager, Life Sciences, Ashland. “Permexa™ sodium caprate was engineered to help customers address complex challenges and move more confidently from formulation through commercialization. The level of engagement we have seen prior to launch demonstrates the importance of solutions that support both drug delivery performance and scalable manufacturing.”
Caroline Cooreman, strategy director, Life Sciences, Ashland, continued, “Consequently, Ashland is not stopping here. We have developed a multi-stage strategy to support the pharmaceutical market with essential excipients for the oral delivery of biologics. We have multiple additional products in the pipeline and recognize important synergies with our vinyl pyrrolidone and derivatives (VP&D) portfolio. We are already actively servicing this market with our established VP&D portfolio, which will be further strengthened by our oral biologics’ portfolio expansion,” she concluded.
For more information about Permexa™ sodium caprate and how the expanded Ashland portfolio of solutions for oral biologics delivery—including product information, technical support and sampling opportunities— interested parties should visit http://ashland.com/permexa or contact their local Ashland solver.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its Annual Report to Stockholders, quarterly reports and other filings with the Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance and financial condition, its strategy as well as the economy and other future events or circumstances.
The risks and uncertainties we face which may cause our actual results to differ materially from the results expressed, projected, or implied in these forward-looking statements include, but are not limited to: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, geopolitical instability and armed conflict, and challenges associated with hiring and managing a diverse workforce across countries with differing laws, regulations, and cultural practices; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, and the inadvertent or accidental disclosure or loss of proprietary or sensitive information; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; and changes in taxation or adverse tax rulings. These risks and uncertainties also include, but are not limited to, the risk factors set forth in Item 1A. “Risk Factors” of Ashland’s most recent Form 10-K, and in our other periodic reports filed with the SEC. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update publicly any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this presentation.
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
™ Trademark, Ashland or its subsidiaries, registered in various countries.
Ashland ve čtvrtletí končícím v červnu 2026 zvýšil tržby na 497 milionů USD, meziročně o 7,3 %, a překonal odhad trhu. EPS ale klesl na 1,02 USD z 1,04 USD.
For the quarter ended June 2026, Ashland (ASH - Free Report) reported revenue of $497 million, up 7.3% over the same period last year. EPS came in at $1.02, compared to $1.04 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $486.24 million, representing a surprise of +2.21%. The company delivered an EPS surprise of -0.97%, with the consensus EPS estimate being $1.03.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Intermediates: $37 million versus the three-analyst average estimate of $33.87 million. The reported number represents a year-over-year change of +12.1%.Revenue- Life Sciences: $180 million versus the three-analyst average estimate of $169.48 million. The reported number represents a year-over-year change of +11.1%.Revenue- Personal Care: $155 million compared to the $154.29 million average estimate based on three analysts. The reported number represents a change of +5.4% year over year.Revenue- Specialty Additives: $136 million compared to the $138.95 million average estimate based on three analysts. The reported number represents a change of +3.8% year over year.Revenue- Intersegment sales: $-11 million compared to the $-9.5 million average estimate based on two analysts. The reported number represents a change of +10% year over year.Adjusted EBITDA- Life Science: $60 million compared to the $55.43 million average estimate based on three analysts.Adjusted EBITDA- Personal Care: $45 million versus the three-analyst average estimate of $45.38 million.Adjusted EBITDA- Specialty Additives: $20 million versus $19.87 million estimated by three analysts on average.Adjusted EBITDA- Intermediates: $4 million versus the three-analyst average estimate of $3.71 million.OPERATING INCOME- Unallocated and other: $-37 million versus the two-analyst average estimate of $-16.5 million.View all Key Company Metrics for Ashland here>>>
Shares of Ashland have returned +3.4% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
